Lifecore Biomedical Inc (LFCR) 뉴스

Form PRE 14A - Other preliminary proxy statements

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Lifecore Biomedical Announces Special Stockholder Meeting

CHASKA, Minn., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a...

Form 8-K - Current report

Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million

Company Believes it is Well Positioned for Mid-Term and Long-Term Growth asCurrent Capacity Continues to...

Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference

CHASKA, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update

-- Recorded Revenues of $32.6 Million for Q2 Fiscal 2025 -- -- Signed Multiple Development Agreements with New...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025

CHASKA, Minn., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a...

Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment

Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities